LifeTechnologies公司（纳斯达克代码：LIFE）是一家致力于改善人类环境的全球生物技术公司。我们的仪器、耗材和服务可协助研究者加速科学探索与开发，从而让生命变得更加美好。我们的客户遍及生物学各个领域，努力加速推进个性化**、再生科学、分子诊断、农业和环境的研究以及21世纪的法医鉴定。生命科技公司2009年的销售额为33亿美元，全球雇员约为9000人，遍及160个国家，并拥有将近3900项知识产权砖利及专有许可证。LifeTechnologies公司由invitrogen公司和AppliedBiosystems公司合并而成，制造体外诊断产品和仅供研究的产品。更多关于我们如何起作用的信息，请访问网站www.lifetechnologies.com。Life Technologies的安全声明

本新闻稿包含关于我们预期结果的前瞻性陈述，且涉及多种风险和不确定因素。本新闻稿中的部分内容，包括但不限于，行业趋势、LifeTechnologies的业务计划、目标、预期和战略的陈述，均包含受各种风险和不确定因素影响的前瞻性陈述，这些风险和不确定因素可能导致实际结果和事件与前瞻性陈述中明示或暗示的有重大差异。任何不属于历史事实的陈述均为前瞻性陈述。可以通过一些特定用词，如\"相信”、\"计划”、\"意图”、\"预期”、\"目标”、\"估计”、\"期望”，和/或将来时态、条件句结构（如\"将”、\"可能”、\"可以”、\"应当”等）或类似的表达方式，来识别一部分前瞻性陈述。可能引发实际结果与前瞻性陈述有重大差异的一些重要因素，在LifeTechnologies向美国证券交易委员会提交的文件中皆有详述。LifeTechnologies不承担任何更新或修改此类前瞻性陈述，以反映后续事件或情形的义务。

LifeTechnologies Readies Researchers for Transition from Benchtop toBedside Tools and reagents pre-configured to supportcell therapy clinical translationCARLSBAD, Calif. – June 16, 2010 – Life Technologies Corporation(NASDAQ: LIFE) today announced the formation of GIBCO® Cell Therapy Systems (CTS™), which will offer the life scienceindustry’s widest array of products to support cell therapyapplications, including regenerative medicine. Specificallydesigned to help cell therapy practitioners accelerate thetransition from research to clinical applications, the productportfolio will include a broad and deep offering of Invitrogendevices and reagents.Cell therapy practitioners today spend a lot of time and moneyassembling and qualifying the tools and reagents required to move acell therapy concept from a laboratory environment to the clinic ina regulatory compliant and highly supported process. Cell-basedtherapies have hundreds of potential applications addressing unmetmedical needs, including neurological disorders, heart disease,cancer, auto-immune disease, infectious disease, as well as tissuerepair where conventional pharmaceuticals may be ineffective. Withthe regenerative medicine field experiencing explosive growth, from$1.6 billion to $15 - $20 billion over the next 15 years1, LifeTechnologies is building a portfolio of bundled tools and reagentsto address this challenge and help researchers accelerate theprocess of moving their potential solutions into a clinicalenvironment.\"Documentation is a critical aspect of bringing novel celltherapies to the clinic,” said Dr. Larry Couture, Senior VicePresident and Founding Director of the Center for AppliedTechnology Development; Director for the Center for Biomedicine andGenetics at the City of Hope in Duarte, California. \"Having properquality systems in place, appropriate documentation, and a stablesupply chain is critical, both in the pre-clinical developmentphase, as well as further down the road during clinicaltrials.”The CTS product portfolio will provide media, reagents, enzymes,buffers, growth factors, selection-beads and magnets, and othercomponents of integrated workflow solutions. The high-qualitymaterials will come with easily accessible documentation, such ascertificates of analysis and certificates of origin. Moreover, theproducts will be backed up with the highest level of technical,regulatory and web-based support.\"We’ve leveraged our expertise, as well as our broad and deepproduct portfolio to create workflow solutions for cell therapythat will help investigators move their research applications intothe clinic more quickly and efficiently, while enhancing patientsafety,” said Paul Pickering, General Manager of Cell TherapySystems at Life Technologies. \"We anticipate that this offeringwill enable us to form collaborations with key industry leaders,and help reduce their burden in qualifying tools and reagents asthey prepare to move their cell therapy concepts into the clinic,which will ultimately help improve the human condition and addressunmet medical need.”1 Scientia Advisors new market review, quoted in April 23, 2010article from Fierce Biotech.About Life TechnologiesLife Technologies Corporation (NASDAQ: LIFE) is a globalbiotechnology tools company dedicated to improving the humancondition. Our systems, consumables and services enable researchersto accelerate scientific exploration, driving to discoveries anddevelopments that make life even better. Life Technologiescustomers do their work across the biological spectrum, working toadvance personalized medicine, regenerative science, moleculardiagnostics, agricultural and environmental research, and 21stcentury forensics. Life Technologies had sales of $3.3 billion in2009, employs approximately 9,000 people, has a presence inapproximately 160 countries, and possesses a rapidly growingintellectual property estate of approximately 3,900 patents andexclusive licenses. Life Technologies was created by thecombination of Invitrogen Corporation and Applied Biosystems Inc.,and manufactures both in-vitro diagnostic products and research useonly-labeled products. For more information on how we are making adifference, please visit our website:http://www.lifetechnologies.com.Safe Harbor StatementThis press release includes forward-looking statements about ouranticipated results that involve risks and uncertainties. Some ofthe information contained in this press release, including, but notlimited to, statements as to industry trends and LifeTechnologies\'\'\'\'\'\'\'\'\'\'\'\'\'\'\'\'\'\'\'\'\'\'\'\'\'\'\'\'\'\'\'\' plans, objectives,expectations and strategy for its business, containsforward-looking statements that are subject to risks anduncertainties that could cause actual results or events to differmaterially from those expressed or implied by such forward-lookingstatements. Any statements that are not statements of historicalfact are forward-looking statements. When used, the words\"believe,\" \"plan,\" \"intend,\" \"anticipate,\" \"target,\" \"estimate,\"\"expect\" and the like, and/or future tense or conditionalconstructions (\"will,\" \"may,\" \"could,\" \"should,\" etc.), or similarexpressions, identify certain of these forward-looking statements.Important factors which could cause actual results to differmaterially from those in the forward-looking statements aredetailed in filings made by Life Technologies with the Securitiesand Exchange Commission. Life Technologies undertakes no obligationto update or revise any such forward-looking statements to reflectsubsequent events or circumstances.Products are For Research Use Only. Not intended for any animal orhuman therapeutic or diagnostic use.Life Technologies Contact上一篇：进口抗体下一篇：第九届国际科学仪器及实验室装备展览会